## Marc H Scheetz

### List of Publications by Citations

Source: https://exaly.com/author-pdf/2917856/marc-h-scheetz-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

4,399 200 39 57 h-index g-index citations papers 5,499 222 4.9 5.73 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
200	Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. <i>Journal of Urology</i> , <b>2012</b> , 187, 1275-9	2.5	203
199	Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 39, 425-9	4.4	173
198	Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5131-3	5.9	116
197	Syphilis. <i>BMJ, The</i> , <b>2007</b> , 334, 143-7	5.9	94
196	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 1621-6	5.9	79
195	1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin Tazobactam. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S483-S483	1	78
194	1548. Characterizing Cefepime Neurotoxicity: Experience from a Tertiary Care Center Performing Elactam Therapeutic Drug Monitoring. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S565-S565	1	78
193	2000. Utilization of a Never Event[Framework to Classify Antimicrobial Appropriateness. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S670-S671	1	78
192	1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S574-S575	1	78
191	1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S427-S427	1	78
190	1871. Identifying Time Periods of High and Low Vancomycin Use. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S535-S535	1	78
189	1821. Understanding the Components and Calculation of the SAAR, Illustrative Data. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S517-S518	1	78
188	209. Impact of a Risk-based CAP Prescribing Guideline Paired with Antimicrobial Stewardship to Improve Antibiotic Prescribing for Patients at Low Risk for Drug-Resistant Pathogens. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S91-S91	1	78
187	1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S437-S438	1	78
186	1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S429-S429	1	78
185	Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 2256-9	5.9	76
184	Effects on patient care caused by drug shortages: a survey. <i>Journal of Managed Care Pharmacy</i> , <b>2013</b> , 19, 783-8		71

## (2013-2012)

183	bacteria according to carbapenem MIC stratification. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 4885-90	5.9	64
182	Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1881-1887	11.6	63
181	The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. <i>American Journal of Therapeutics</i> , <b>2009</b> , 16, 508-11	1	63
180	Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4844-9	5.9	61
179	Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 816-25	5.1	59
178	Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1793-6	5.9	58
177	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1386-1388	2.4	56
176	Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 562-84	5.8	56
175	Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 539-50	5.8	56
174	Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. <i>Clinical Therapeutics</i> , <b>2010</b> , 32, 1713-9	3.5	55
173	Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 31	4	54
172	The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious	11.6	54
171	Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5232-	· <b>§</b> ··9	52
170	Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59 Suppl 3, S162-9	11.6	51
169	Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 1106-9	9.7	51
168	Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1256-63	5.8	47
167	Antimicrobial stewardship programs: methods of operation and suggested outcomes. <i>Expert Review of Anti-Infective Therapy</i> , <b>2012</b> , 10, 63-73	5.5	46
166	Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 3969-75	5.9	45

165	Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 460-5	5.9	44
164	Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	42
163	Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 574	2 <sup>5</sup> 59	42
162	The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 684-91	11.6	39
161	Posaconazole: an oral triazole with an extended spectrum of activity. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 1429-38	2.9	39
160	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. <i>Clinical Microbiology and Infection</i> , <b>2018</b> , 24, 1070-1076	9.5	35
159	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 60, 1401-10	5.9	35
158	Systematic review of piperacillin-induced neutropenia. <i>Drug Safety</i> , <b>2007</b> , 30, 295-306	5.1	35
157	Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1074-9	5.9	34
156	A Review of the Clinical Pharmacokinetics of Polymyxin B. <i>Antibiotics</i> , <b>2019</b> , 8,	4.9	33
155	Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1734-9	2.9	33
154	Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. <i>Transplantation</i> , <b>2007</b> , 83, 874-82	1.8	33
153	Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 2285-90	5.1	32
152	Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 1352-6	4.4	32
151	Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. <i>Drug Safety</i> , <b>2009</b> , 32, 147-58	5.1	32
150	Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 3355-60	5.9	32
149	Evaluation of a potential clinical interaction between ceftriaxone and calcium. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1534-40	5.9	31
148	Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2068-73	5.1	30

# (2020-2010)

147	Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. <i>Annals of Pharmacotherapy</i> , <b>2010</b> , 44, 582-6	2.9	29
146	Morbidity associated with Pseudomonas aeruginosa bloodstream infections. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 64, 311-9	2.9	28
145	Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii. <i>Annals of Pharmacotherapy</i> , <b>2011</b> , 45, 218-28	2.9	26
144	Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 429-433	5.1	25
143	Mechanisms of antimicrobial-induced nephrotoxicity in children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1-13	5.1	25
142	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 730-738	5.8	24
141	Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	23
140	Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	23
139	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	22
138	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 2326	-2334	21
137	Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5854-9	5.9	21
136	Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 1098-100	9.7	21
135	Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 905-7	11.6	20
134	Prospective approach to managing antimicrobial drug shortages. <i>Infection Control and Hospital Epidemiology</i> , <b>2012</b> , 33, 745-52	2	20
133	An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , <b>2016</b> , 22, 78-83	2.2	19
132	Peritoneal fluid penetration of tigecycline. <i>Annals of Pharmacotherapy</i> , <b>2006</b> , 40, 2064-7	2.9	19
131	Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1228-1236	5.1	18
130	Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 438-454	5.8	18

129	Biopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity. <i>International Journal of Nephrology</i> , <b>2011</b> , 2011, 436856	1.7	18
128	Prevalence of a Cefazolin Inoculum Effect Associated with Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	17
127	Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. <i>Journal of Urology</i> , <b>2013</b> , 190, 2026-32	2.5	17
126	Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2015</b> , 82, 165-71	2.9	16
125	Preventing the Post-Antibiotic Era by Training Future Pharmacists as Antimicrobial Stewards. American Journal of Pharmaceutical Education, <b>2018</b> , 82, 6770	2.5	16
124	Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 31-43	8.8	16
123	The association of elevated trough serum vancomycin concentrations with obesity. <i>Journal of Infection and Chemotherapy</i> , <b>2015</b> , 21, 507-11	2.2	15
122	Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 184-9	5.9	15
121	Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. <i>American Journal of Health-System Pharmacy</i> , <b>2006</b> , 63, 1346-60	2.2	15
120	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 561-572	6.2	15
119	Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest MIC values of 1.5mg/L: A pilot study. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2017</b> , 88, 259-263	2.9	14
118	Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. <i>Drug Safety</i> , <b>2013</b> , 36, 335-47	5.1	14
117	Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 426-432	11.6	14
116	Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 51, 239-243	14.3	14
115	Periarrest intestinal bacterial translocation and resuscitation outcome. <i>Journal of Critical Care</i> , <b>2016</b> , 31, 217-20	4	13
114	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 487-490	14.3	13
113	Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-Elactamase-producing Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3757-61	5.9	13
112	Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study.  Open Forum Infectious Diseases, 2020, 7, ofaa538	1	13

## (2017-2017)

111	Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2017</b> , 42, 350-355	2.2	12	
110	Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. <i>International Journal of Antimicrobial Agents</i> , <b>2010</b> , 36, 94-5	14.3	12	
109	Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. <i>Annals of Pharmacotherapy</i> , <b>2011</b> , 45, e64	2.9	12	
108	Critical Need for Clarity in Polymyxin B Dosing. Antimicrobial Agents and Chemotherapy, <b>2017</b> , 61,	5.9	11	
107	Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 482-486	14.3	11	
106	Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 354-60	5.8	11	
105	Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 53, 225-233	14.3	11	
104	Engaging Pharmacy Students in Research Through Near-Peer Training. <i>American Journal of Pharmaceutical Education</i> , <b>2017</b> , 81, 6340	2.5	10	
103	Carbapenems vs. alternative Elactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 52, 451-458	14.3	10	
102	Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 436-7; author reply 437-8	11.6	10	
101	Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling? <b>2021</b> , 3, e0446		10	
100	Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 838-44	5.9	9	
99	Significant publications on infectious diseases pharmacotherapy in 2008. <i>American Journal of Health-System Pharmacy</i> , <b>2009</b> , 66, 1726-34	2.2	9	
98	An analysis of the accuracy of physician-entered indications on computerized antimicrobial orders. <i>Infection Control and Hospital Epidemiology</i> , <b>2012</b> , 33, 1066-7	2	9	
97	In vivo synergy of daptomycin plus a penicillin agent for MRSA?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2005</b> , 55, 398-9	5.1	9	
96	Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 241-6	2.2	9	
95	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	8	
94	High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin. <i>Clinical and Translational Science</i> , <b>2017</b> , 10, 496-502	4.9	8	

93	Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. <i>American Journal of Health-System Pharmacy</i> , <b>2013</b> , 70, 1163-	6 <sup>2.2</sup>	8
92	Characterization of Acinetobacter baumannii genotypes recovered from patients with repeated colonization or infection. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 65, 1-6	2.9	8
91	Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. <i>EBioMedicine</i> , <b>2021</b> , 63, 103204	8.8	8
90	Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections. <i>Journal of Infection and Chemotherapy</i> , <b>2016</b> , 22, 671-6	2.2	7
89	Investigating the Extremes of Antibiotic Use with an Epidemiologic Framework. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3265-9	5.9	7
88	Impact of vancomycin treatment duration and dose on kidney injury. <i>International Journal of Antimicrobial Agents</i> , <b>2014</b> , 43, 297-8	14.3	7
87	Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 401	4	7
86	Projections for antiinfective drug shortages and time to actual resolution. <i>American Journal of Health-System Pharmacy</i> , <b>2014</b> , 71, 2074-8	2.2	7
85	Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 64, 465-	7.9	7
84	Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 1221-8	5.8	7
83	The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2006</b> , 56, 407-13	2.9	7
82	Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia. <i>Journal of Infection</i> , <b>2006</b> , 52, 105-10	18.9	7
81	The Pharmacodynamic-Toxicodynamic Relationship of AUC and in Vancomycin-Induced Kidney Injury in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	7
80	Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 49, 650-654	14.3	6
79	Development of a pharmacy student research program at a large academic medical center. American Journal of Health-System Pharmacy, <b>2015</b> , 72, 1885-9	2.2	6
78	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 21, 83-85	3.4	6
77	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest[] macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 534	4	6
76	Carbapenem susceptibility breakpoints, clinical implications with the moving target. <i>Expert Review of Anti-Infective Therapy</i> , <b>2016</b> , 14, 389-401	5.5	6

75	Developing a Method for Reporting Patient Harm Due to Antimicrobial Shortages. <i>Infectious Diseases and Therapy</i> , <b>2014</b> , 3, 349-55	6.2	6
74	Pathogenicity of clinical Acinetobacter baumannii isolates in a Galleria mellonella host model according to bla(OXA-40) gene and epidemiological outbreak status. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 1240-2	5.9	6
73	Effective use of a clinical decision-support system to advance antimicrobial stewardship. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 1543-4	2.2	6
72	Virulence of vancomycin-resistant Enterococcus faecium according to linezolid resistance and clinical outbreak status. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 3923-7	5.9	6
71	Genome Sequences of Five Clinical Isolates of Klebsiella pneumoniae. <i>Genome Announcements</i> , <b>2016</b> , 4,		6
70	It is time to define antimicrobial never events. <i>Infection Control and Hospital Epidemiology</i> , <b>2019</b> , 40, 206	5-2207	6
69	Targeting of Escherichia coli with Vancomycin-Arginine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	6
68	Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection. <i>American Journal of Infection Control</i> , <b>2018</b> , 46, 270-275	3.8	6
67	Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1575-1587	6.2	5
66	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1027-1036	6.2	5
65	The Emperor New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S30-S31	1	5
64	Temporal changes in pulsed-field gel electrophoresis banding in vancomycin-resistant Enterococcus faecium and implications for outbreak investigations. <i>American Journal of Infection Control</i> , <b>2013</b> , 41, 349-53	3.8	5
63	Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumption. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2017</b> , 89, 72-77	2.9	5
62	Pharmacokinetics of centhaquin citrate in a rat model. <i>Journal of Pharmacy and Pharmacology</i> , <b>2016</b> , 68, 56-62	4.8	5
61	Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0106	5 <b>52</b> 1	5
60	Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing. Journal of Infection and Chemotherapy, <b>2017</b> , 23, 326-332	2.2	4
59	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	4
58	Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest. <i>Paediatric Drugs</i> , <b>2019</b> , 21, 107-112	4.2	4

57	Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	4
56	Pharmacokinetics of centhaquin citrate in a dog model. <i>Journal of Pharmacy and Pharmacology</i> , <b>2016</b> , 68, 803-9	4.8	4
55	Empiric antibiotic selection for infectious emergencies: bacterial pneumonia, meningitis and sepsis. Drugs of Today, <b>2009</b> , 45, 379-93	2.5	4
54	The case for precision dosing: medical conservatism does not justify inaction. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1661-1665	5.1	4
53	Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation. <i>Pharmacotherapy</i> , <b>2016</b> , 36, 1003-10	5.8	4
52	Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital		4
51	Does renal function matter for polymyxin B?. British Journal of Clinical Pharmacology, 2021, 87, 2629-26	<b>33</b> 8	3
50	Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics. <i>Infection Control and Hospital Epidemiology</i> , <b>2016</b> , 37, 971-973	2	3
49	Measuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmes. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 2876-2882	5.1	3
48	Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	3
47	Empty shelves, full of frustration: consequences of drug shortages and the need for action. <i>Hospital Pharmacy</i> , <b>2013</b> , 48, 617-8	1.1	3
46	Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 469-79	5.8	3
45	Elactam dosing strategies: Think before you push. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106151	14.3	3
44	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 491-495	3.5	3
43	Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 53, 95-97	14.3	3
42	A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19. <i>Clinical Therapeutics</i> , <b>2021</b> , 43, e57-e70	3.5	3
41	A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization. <i>Infection Control and Hospital Epidemiology</i> , <b>2017</b> , 38, 860-862	2	2
40	Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , <b>2015</b> , 21, 742-6	2.2	2

39	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 55, 105970	14.3	2
38	Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections. <i>Journal of Global Antimicrobial Resistance</i> , <b>2018</b> , 13, 261-263	3.4	2
37	Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique. <i>Clinical Transplantation</i> , <b>2013</b> , 27, 154-61	3.8	2
36	Novel work models needed for faculty members trying to balance clinical practice with scholarly responsibilities. <i>American Journal of Pharmaceutical Education</i> , <b>2014</b> , 78, 21	2.5	2
35	Need for standardization in assessing impact of antibiotic shortages on patient outcomes. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 2129-30	2.2	2
34	Effect of on-call infectious-diseases pharmacists on antibiotic expenditures. <i>American Journal of Health-System Pharmacy</i> , <b>2005</b> , 62, 1967-8	2.2	2
33	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> , 10, 1525	4.5	2
32	Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. <i>Implementation Science Communications</i> , <b>2021</b> , 2, 34	2.2	2
31	Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. <i>journal of applied laboratory medicine, The</i> , <b>2021</b> , 6, 1202-1212	2	2
30	Supporting Precision Dosing in Drug Labeling. Clinical Pharmacology and Therapeutics, 2021, 109, 37-41	6.1	2
29	Exploring the Relationship between FEV Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 584-591	5.8	1
28	Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice. <i>International Journal of Clinical Pharmacy</i> , <b>2011</b> , 33, 537-42	2.3	1
27	Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Bloodstream Infections <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab651	1	1
26	Glomerular function and urinary biomarker changes between vancomycin and vancomycin plus piperacillin-tazobactam in a translational rat model <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , aact	021322	2Ť
25	Microsampling Assays for Pharmacokinetic Analysis and Therapeutic Drug Monitoring of Antimicrobial Drugs in Children: A Critical Review. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 335-345	3.2	1
24	Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model		1
23	Early Switch From Vancomycin to Daptomycin in Methicillin-Resistant Staphylococcus aureus Bacteremia: Still More Questions Than Answers. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1128-1129	11.6	1
22	Precision dosing of vancomycin: in defence of AUC-guided therapy in children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2494-2497	5.1	1

21	1569. A Translational Model to Assess the Impact of Polymyxin B Dose Fractionation on Kidney Injury. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S573-S574	1	1
20	2010. A Significant Reduction in Empiric Vancomycin Days of Therapy for Suspected MRSA Pneumonia in Adult Non-ICU Patients After Implementation of a Rapid MRSA Nasal PCR Test with Antimicrobial Stewardship Intervention. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S674-S675	1	1
19	Understanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR). <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	1
18	Vancomycin Duration of Therapy Can Inform the Need for Area Under the Curve Monitoring. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1235-e1236	11.6	O
17	Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin. <i>Journal of Hospital Medicine</i> , <b>2020</b> , 15, 740-742	2.7	O
16	Cefepime precision dosing tool: From Standard to Precise Dose Using Nonparametric Population Pharmacokinetics <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , AAC0204621	5.9	O
15	A Translational Rat Model to Assess Glomerular Function Changes with Vancomycin <i>International Journal of Antimicrobial Agents</i> , <b>2022</b> , 106583	14.3	O
14	Urinary Metabolomics from a Dose-Fractionated Polymyxin B Rat Model of Acute Kidney Injury <i>International Journal of Antimicrobial Agents</i> , <b>2022</b> , 106593	14.3	O
13	In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1153	6.4	O
12	Analysis of an Infectious Diseases Pharmacist on Call Pager Program to Inform Educational Efforts. Journal of Pharmacy Technology, <b>2017</b> , 33, 146-150	0.6	
11	1395Reporting of Unit-Specific, Culture Site-Specific Antimicrobial Susceptibility for Gram-Negative Bacteria: Identification of Significant Differences in Susceptibility, Intervention to Guide Empiric Therapy and Impact on Antimicrobial Consumption. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, S367-S367	1	
10	The Impact of Qualitative Respiratory Cultures on Mortality in Critically III Patients with Hospital-Acquired Pneumonia. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 624-633	1.1	
9	Impact of early antimicrobial stewardship intervention in patients with positive blood cultures: results from a randomized comparative study: Impact of stewardship on BSI outcomes. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 59, 106490	14.3	
8	238. Novel Way to Evaluate Antibiotic Use Appropriateness: Moving Towards the Never Event Classification by Electronic Algorithm. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S119-S120	1	
7	Writing and Thinking. American Journal of Pharmaceutical Education, 2019, 83, 7785	2.5	
6	Development of ELLA Approach to Measure Kidney Injury Molecule-1. FASEB Journal, 2020, 34, 1-1	0.9	
5	Antimicrobial never events: Objective application of a framework to assess vancomycin appropriateness. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 1121-1123	2	
4	Implementing a Continuous or Prolonged Infusion Beta-Lactam Program in the Hospital Setting. <i>Methods in Pharmacology and Toxicology</i> , <b>2016</b> , 507-536	1.1	

#### LIST OF PUBLICATIONS

 ${\it 3} \qquad {\it What Every Steward Should Know About Pharmacokinetics and Pharmacodynamics} {\it 155-174}$ 

2	1090. Does calculation method matter for targeting vancomycin AUC?. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S636-S636	1
1	Vancomycin Pharmacokinetics in a Pregnancy Rat Model <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> . e0005622	5.9